Literature DB >> 20943965

Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif.

Jessica L Smith1, Vinay K Pathak.   

Abstract

Human APOBEC3F (hA3F) and human APOBEC3G (hA3G) are potent anti-human immunodeficiency virus (anti-HIV) host factors that suppress viral replication by hypermutating the viral genome, inhibiting reverse transcription, and hindering integration. To overcome hA3F and hA3G, HIV-1 encodes Vif, which binds and targets these host proteins for proteasomal degradation. Previously, we reported that the hA3F-Vif interactions that lead to hA3F degradation are located in the region comprising amino acids 283 to 300. We have now performed mutational analysis of this region and found that the (289)EFLARH(294) amino acids contribute to hA3F-Vif binding and are critical for A3F's sensitivity to Vif. Mutants in which E289 is mutated significantly increase hA3F's ability to inhibit viral infectivity in the presence of Vif, and coimmunoprecipitation assays show that binding of Vif to the E289K mutant is decreased. We examined the role of the EFLARH sequence in other A3 proteins, including human A3C (hA3C), human A3DE (hA3DE), African green monkey A3F (agmA3F), and rhesus macaque A3F (rhA3F). hA3C, hA3DE, and agmA3F were all susceptible to degradation induced by HIV-1 Vif, while rhA3F was not. Mutagenesis of the glutamate in the EFLARH sites of hA3C, hA3DE, and agmA3F decreases the susceptibilities of these proteins to Vif-induced degradation. Together, these results indicate that the EFLARH region in hA3F, hA3C, hA3DE, and agmA3F interacts with HIV-1 Vif and that this interaction plays a role in the Vif-mediated proteasomal degradation of these A3 proteins. These studies identify a conserved region in 3 of 7 human A3 proteins that is critical for degradation mediated by HIV-1 Vif and provide structural insights into the hA3F-Vif interactions that could facilitate the development of a novel class of anti-HIV agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20943965      PMCID: PMC3004357          DOI: 10.1128/JVI.01437-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

2.  Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.

Authors:  Ying Dang; Roderick W Davis; Ian A York; Yong-Hui Zheng
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

3.  Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.

Authors:  Andrew Mehle; Joao Goncalves; Mariana Santa-Marta; Mark McPike; Dana Gabuzda
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

4.  APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.

Authors:  Jean L Mbisa; Wei Bu; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

5.  The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex.

Authors:  Julien R C Bergeron; Hendrik Huthoff; Dennis A Veselkov; Rebecca L Beavil; Peter J Simpson; Stephen J Matthews; Michael H Malim; Mark R Sanderson
Journal:  PLoS Pathog       Date:  2010-06-03       Impact factor: 6.823

6.  A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.

Authors:  Anjie Zhen; Tao Wang; Ke Zhao; Yong Xiong; Xiao-Fang Yu
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

7.  A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G.

Authors:  Gongying Chen; Zhiwen He; Tao Wang; Rongzhen Xu; Xiao-Fang Yu
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

8.  A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.

Authors:  Hongzhan Xu; Evguenia S Svarovskaia; Rebekah Barr; Yijun Zhang; Mohammad A Khan; Klaus Strebel; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

9.  APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.

Authors:  Qin Yu; Darlene Chen; Renate König; Roberto Mariani; Derya Unutmaz; Nathaniel R Landau
Journal:  J Biol Chem       Date:  2004-10-04       Impact factor: 5.157

10.  Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.

Authors:  Véronique Zennou; Paul D Bieniasz
Journal:  Virology       Date:  2006-02-07       Impact factor: 3.616

View more
  48 in total

1.  Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.

Authors:  Judd F Hultquist; Joy A Lengyel; Eric W Refsland; Rebecca S LaRue; Lela Lackey; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

2.  Structural Insights into HIV-1 Vif-APOBEC3F Interaction.

Authors:  Masaaki Nakashima; Hirotaka Ode; Takashi Kawamura; Shingo Kitamura; Yuriko Naganawa; Hiroaki Awazu; Shinya Tsuzuki; Kazuhiro Matsuoka; Michiko Nemoto; Atsuko Hachiya; Wataru Sugiura; Yoshiyuki Yokomaku; Nobuhisa Watanabe; Yasumasa Iwatani
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

Review 3.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

4.  The APOBEC3C crystal structure and the interface for HIV-1 Vif binding.

Authors:  Shingo Kitamura; Hirotaka Ode; Masaaki Nakashima; Mayumi Imahashi; Yuriko Naganawa; Teppei Kurosawa; Yoshiyuki Yokomaku; Takashi Yamane; Nobuhisa Watanabe; Atsuo Suzuki; Wataru Sugiura; Yasumasa Iwatani
Journal:  Nat Struct Mol Biol       Date:  2012-09-23       Impact factor: 15.369

Review 5.  Structural insights for HIV-1 therapeutic strategies targeting Vif.

Authors:  Jason D Salter; Guillermo A Morales; Harold C Smith
Journal:  Trends Biochem Sci       Date:  2014-08-12       Impact factor: 13.807

6.  APOBEC3F determinants of HIV-1 Vif sensitivity.

Authors:  Allison M Land; Nadine M Shaban; Leah Evans; Judd F Hultquist; John S Albin; Reuben S Harris
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

7.  Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.

Authors:  Tayyba T Baig; Yuqing Feng; Linda Chelico
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

8.  The in vitro Biochemical Characterization of an HIV-1 Restriction Factor APOBEC3F: Importance of Loop 7 on Both CD1 and CD2 for DNA Binding and Deamination.

Authors:  Qihan Chen; Xiao Xiao; Aaron Wolfe; Xiaojiang S Chen
Journal:  J Mol Biol       Date:  2016-04-08       Impact factor: 5.469

9.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

10.  Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F.

Authors:  John S Albin; John S Anderson; Jeffrey R Johnson; Elena Harjes; Hiroshi Matsuo; Nevan J Krogan; Reuben S Harris
Journal:  J Mol Biol       Date:  2013-01-11       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.